Clinical Trials Logo
  1. Home
  2. Urothelial Carcinoma Bladder
  3. NCT05701332

Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume

Urothelial Carcinoma Bladder Clinical Trial

Official title:
Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume in Patients With Non-muscle Invasive Bladder Cancer Patients

Clinical Trial Summary

To evaluate the effects of local intravesical B.C.G and gemcitabine on semen quality and testicular volume.

Clinical Trial Description

Local chemotherapy has become one of the alternative strategies in treatment of cancer as many side effects on organs in human body. Despite this, also local chemotherapy has adverse effects too. One of these cancers in which local chemotherapy is used and one of the most five prevalent cancers in Egyptian men and the 3rd highest incidence numbers for specific cancer cases in Egypt in 2020,also It represents the 3rd highest mortality number from cancer in Egypt by 19% of men's mortality is bladder cancer. It is divided according to the staging system into 2 main types: the non-muscle invasive (T1) and muscle invasive (T2).The most common method used to treat T1 baldder cancer are TURT followed by local intravesical immunotherapy (like Bacillus Calmette Guerin) and chemotherapy (Gemcitabine and Mitomycin C). These drugs systemically can cause side effects like urgency, frequency, low grade fever, malaise, effect on high proliferative tissues like bone marrow, skin, hair, and seminiferous tubules….etc. Some rare side effects are acute respiratory distress syndrome and hepatic toxicity. The effect of these drugs on seminiferous tubules is still a controversy as most of the research field is focusing on systemic use, also the lack of researches focusing on local intravesical use. It can cause infertility especially in young patients with cancer who seek fertility and they are not married or not having children. The problem of fertility and urogenital cancer is multifactorial and there is a gap of knowledge as low incidence number of bladder cancer in young patients and the lack of he studies focusing on fertility in cancer patients. This study is going to unmask the mystery of one of local immunotherapy and immunotherapy and there effect on semen and testicles. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05701332
Study type Interventional
Source Assiut University
Contact Ahmed A Elsayed, resident
Phone +2 01065973921
Email ahmed.14223921@med.aun.edu.eg
Status Not yet recruiting
Phase Phase 4
Start date April 1, 2023
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03606174 - A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma Phase 2
Recruiting NCT05839119 - Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant Phase 1
Completed NCT03558503 - A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Phase 2
Completed NCT05136898 - Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) Phase 3
Withdrawn NCT06090318 - Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Phase 1/Phase 2
Recruiting NCT03185468 - Intervention of Bladder Cancer by CAR-T Phase 1/Phase 2
Active, not recruiting NCT05243550 - A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Phase 3
Recruiting NCT05312671 - Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer Phase 2
Recruiting NCT02951325 - Bladder Cancer Adjuvant Radiotherapy Trial N/A
Recruiting NCT05401279 - Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05375903 - A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Phase 1
Active, not recruiting NCT04386746 - Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer Phase 2
Recruiting NCT06184516 - Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy Phase 2
Not yet recruiting NCT06331299 - A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer Phase 3
Not yet recruiting NCT05656235 - Renal Retention in High Grade Upper Tract Urothelial Cancer Phase 2
Not yet recruiting NCT05037279 - Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Phase 3
Terminated NCT04688931 - A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer Phase 3
Recruiting NCT05241340 - Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05077709 - IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC Phase 2
Completed NCT04200963 - A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Phase 1